Industry News

The College of William and Mary is engaged in a $25 million renovation and expansion of the William Small Physical Laboratory in Williamsburg, Va. Adding two new wings, the project will increase research lab space in the existing 67,000-sf facility from 11,300-sf to 23,000-sf. One wing will house high-bay space with an interior crane and the second wing will feature modular laboratories for ease of reconfiguration. The renovated facility will also include a computing lab for simulation and research, low vibration research space, and a cleanroom.

Kellogg Company is engaged in a $54 million expansion of the W.K. Kellogg Institute for Food and Nutrition Research in Battle Creek, Mich. Slated for completion in fall of 2009, the expanded facility will encompass 400,000-sf of laboratory, office, and pilot plant manufacturing space. Kellogg is also planning to build a $25 million office tower in Battle Creek.

Northern Inyo Hospital has selected Turner Construction to manage a $42 million expansion of its healthcare facility in Bishop, Calif. The project represents the second expansion phase at the hospital and will commence in March of 2009. Completion is slated for March of 2011. A two-story building will house 26 patient rooms, emergency rooms, ICU, CCU, and three operating suites. A new central plant will also be constructed.

The University of North Carolina at Charlotte is planning to construct the $76 million Energy Production and Infrastructure Center (EPIC) on the Charlotte Research Institute campus. Designed by Narmour Wright Creech Architects, the 200,000-sf collaborative teaching and research facility will house the departments of Civil & Environmental Engineering and Electrical Engineering. Groundbreaking is expected in late summer of 2009 with completion slated for 2011.

The U.S. Department of Health and Human Services awarded Novartis a $486 million contract in early 2009 to build pandemic flu vaccine manufacturing facilities in Holly Springs, N.C. The funding will support the design, construction, and validation of flu vaccine production centers over the next eight years, enabling Novartis to supply 150 million doses of cell-based influenza vaccine within six months of the onset of a pandemic.